BioCentury
ARTICLE | Company News

Inspire, Boehringer epinastine deal

February 22, 2006 2:23 AM UTC

Boehringer Ingelheim (Ingelheim, Germany) granted ISPH exclusive rights to develop and market intranasal epinastine in the U.S. and Canada to treat or prevent rhinitis. ISPH expects to start a Phase I...